D. Middleton

发表

An in situ oxidation strategy towards overcoming hERG affinity.

D. Pryde, Rhys M. Jones, D. Middleton, 2010, Bioorganic & medicinal chemistry letters.

1-Amido-1-phenyl-3-piperidinylbutanes--CCR5 antagonists for the treatment of HIV: part 2.

J. Chiva, D. Blakemore, D. Middleton, 2009, Bioorganic & medicinal chemistry letters.

1-Amido-1-phenyl-3-piperidinylbutanes - CCR5 antagonists for the treatment of HIV. Part 1.

J. Chiva, D. Blakemore, D. Middleton, 2009, Bioorganic & medicinal chemistry letters.

The design and discovery of novel amide CCR5 antagonists.

David W. Gordon, D. Gordon, A. Wood, 2009, Bioorganic & medicinal chemistry letters.

Chapter 16. Therapeutic applications of non-peptidic δ-opioid agonists graham

G. Maw, D. Middleton, 2002 .

Novel indazole non-nucleoside reverse transcriptase inhibitors using molecular hybridization based on crystallographic overlays.

Catherine Burt, Chris Phillips, T. Knöchel, 2009, Journal of medicinal chemistry.

Novel selective inhibitors of neutral endopeptidase for the treatment of female sexual arousal disorder.

P. H. van der Graaf, K. Beaumont, A. Stobie, 2007, Bioorganic & medicinal chemistry.

Inhalation by design: novel tertiary amine muscarinic M₃ receptor antagonists with slow off-rate binding kinetics for inhaled once-daily treatment of chronic obstructive pulmonary disease.

M. Bunnage, David A. Price, A. Wood, 2011, Journal of medicinal chemistry.

Furazans and furazan oxides. V. Tropono[4,5-c]-, thieno[2,3-c]-, and biphenyleno[2,3-c]furazan oxides

D. Middleton, A. Boulton, 1974 .

Tandem Inter [4 + 2]/Intra [3 + 2] Cycloadditions. 17. The Spiro Mode. Efficient and Highly Selective Synthesis of Azapropellanes

S. Denmark, D. Middleton, 1998 .

Total synthesis of (±)-fredericamycin A. Use of radical spirocyclization

C. Boddy, D. Clive, Yong-Jin Wu, 1992 .

Synthesis of spiroethers using radical cyclisations

N. Terrett, N. Simpkins, D. Middleton, 1990 .

Facile synthesis of functionalised spiroethers via radical cyclisations

N. Terrett, N. Simpkins, D. Middleton, 1988 .

Comparison of the Non‐Nucleoside Reverse Transcriptase Inhibitor Lersivirine with its Pyrazole and Imidazole Isomers

Chris Phillips, R. Corbau, C. Mowbray, 2011, Chemical biology & drug design.

Stereoselective Synthesis of Silacyclohexanols by Silicon Tethered Type II Ene Cyclisation

J. Robertson, D. Middleton, Tsarina Sardharwala, 2000 .

Silicon tethered type II ene cyclisations

J. Robertson, D. Middleton, Garry O'connor, 1996 .

Total synthesis of crystalline (±)-fredericamycin A

D. Cheshire, C. Boddy, D. Clive, 1995 .

A mild method for the preparation of functionalised, unsymmetrical ketene acetals.

N. Simpkins, D. Middleton, 1989 .

Tandem Inter [4 + 2]/Intra [3 + 2] Cycloadditions. Part 17. The Spiro Mode. Efficient and Highly Selective Synthesis of Azapropellanes.

S. Denmark, D. Middleton, 1998 .

The reaction of dibenzoylfuroxan with phenylacetylene, styrene and stilbene

D. Middleton, A. Boulton, M. Altaf-ur-Rahman, 1972 .

Practical synthetic routes to carbon-substituted nucleosides

D. Pryde, D. Middleton, P. T. Stephenson, 2011 .

Oxasilacyclopentanes as intermediates for silicon tethered ene cyclisations

J. Robertson, D. Middleton, Tsarina Sardharwala, 1998 .

Model studies related to the synthesis of fredericamycin A

D. Clive, D. Middleton, C. Lowe, 1991 .

A General Strategy for the Synthesis of Cis-Substituted Pyrrolizidine Bases. The Synthesis of (-)-Rosmarinecine

S. Denmark, A. Thorarensen, D. Middleton, 1995 .

Synthesis and Biological Evaluation of Acyclic Phosphonic Acid Nucleoside Derivatives

D. Pryde, S. Sutton, D. Middleton, 2013, Nucleosides, nucleotides & nucleic acids.

Optimization of 5‐Aryloxyimidazole Non‐Nucleoside Reverse Transcriptase Inhibitors

R. Corbau, D. Hay, C. Mowbray, 2008, ChemMedChem.

Cytochrome P450 metabolism and inhibition: analysis for drug discovery.

Kuresh Youdim, Barry C Jones, K. Youdim, 2009, Progress in medicinal chemistry.

An imidazopiperidine series of CCR5 antagonists for the treatment of HIV: the discovery of N-{(1S)-1-(3-fluorophenyl)-3-[(3-endo)-3-(5-isobutyryl-2-methyl-4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridin-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]propyl}acetamide (PF-232798).

A. Wood, P. Dorr, D. Pryde, 2011, Journal of medicinal chemistry.

Designing rapid onset selective serotonin re-uptake inhibitors. Part 1: Structure-activity relationships of substituted (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydro-1-naphthaleneamine.

M. Andrews, Malcolm C. Mackenny, M. J. Pitcher, 2006, Bioorganic & medicinal chemistry letters.

Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction.

D. Hay, I. Gardner, C. Mowbray, 2009, Bioorganic & medicinal chemistry letters.

Synthesis of N-protected spiroamines related to natural products using radical cyclisations

N. Terrett, N. Simpkins, D. Middleton, 1989 .

Synthesis of N-Protected Spiroamines Related to Natural Products Using Radical Cyclizations.

N. Terrett, N. Simpkins, D. Middleton, 1990 .

Structure-activity relationships of 1-alkyl-5-(3,4-dichlorophenyl)- 5-[2-[(3-substituted)-1-azetidinyl]ethyl]-2-piperidones. 1. Selective antagonists of the neurokinin-2 receptor.

B. Jones, D. Middleton, Sandra D. Newman, 2002, Journal of medicinal chemistry.

Highly potent and selective zwitterionic agonists of the δ-opioid receptor. Part 1

M. Trevethick, Alan S. Jessiman, Carly L. Nichols, 2006 .

Non-benzimidazole containing inhibitors of respiratory syncytial virus.

I. Gardner, D. Pryde, T. Parkinson, 2013, Bioorganic & medicinal chemistry letters.

Designing rapid onset selective serotonin re-uptake inhibitors. Part 3: Site-directed metabolism as a strategy to avoid active circulating metabolites: structure-activity relationships of (thioalkyl)phenoxy benzylamines.

M. Andrews, Malcolm C. Mackenny, D. Hepworth, 2008, Bioorganic & medicinal chemistry letters.